pubmed.ncbi.nlm.nih.gov

Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli - PubMed

Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli

N A Strockbine et al. Infect Immun. 1985 Dec.

Abstract

Three monoclonal antibodies, designated MAb 16E6, MAb 13C4, and MAb 19G8, were produced which recognize Shiga-like toxin (SLT) from Escherichia coli. All three monoclonal antibodies neutralized the cytotoxicity of E. coli SLT and were able to immunoprecipitate intact labeled toxin with Staphylococcus aureus protein A. The three antibodies were of the G1 heavy and kappa light chain classes. MAb 16E6 bound to the B subunit of SLT in Western blots and also neutralized the lethality of the toxin for mice and the enterotoxicity of the toxin in ligate rabbit ileal loops. The ability of MAb 16E6 to neutralize the cytotoxicity, lethality, and enterotoxicity of E. coli confirms the hypothesis that all three activities are associated with a single toxin. MAb 16E6 and MAb 13C4 also neutralized the cytotoxicity of purified Shiga toxin from Shigella dysenteriae type 1 and Shiga-like toxic activities in crude cell extracts from Shigella flexneri, Vibrio cholerae, Vibrio parahaemolyticus, and Salmonella typhimurium. Thus, Shiga toxin and the SLTs from E. coli, Shigella flexneri, V. cholerae, V. parahaemolyticus, and Salmonella typhimurium share a common B subunit epitope that is involved in neutralization. MAb 13C4 has been successfully used in a colony blot assay for the detection of bacterial colonies which produce high levels of SLT. Sixty-two different strains of bacteria were tested by both the cytotoxicity and colony blot assays for the presence of SLT. The colony blot assay detected all strains of bacteria which produce greater than or equal to 10(5) 50% cytotoxic doses of SLT per ml of sonic lysate. There were no false-positive results among the 62 samples tested.

PubMed Disclaimer

Cited by

Unusual verotoxin-producing Escherichia coli associated with hemorrhagic colitis.
Bopp CA, Greene KD, Downes FP, Sowers EG, Wells JG, Wachsmuth IK. Bopp CA, et al. J Clin Microbiol. 1987 Aug;25(8):1486-9. doi: 10.1128/jcm.25.8.1486-1489.1987. J Clin Microbiol. 1987. PMID: 3305564 Free PMC article.
Cloning and sequencing of the genes for Shiga toxin from Shigella dysenteriae type 1.
Strockbine NA, Jackson MP, Sung LM, Holmes RK, O'Brien AD. Strockbine NA, et al. J Bacteriol. 1988 Mar;170(3):1116-22. doi: 10.1128/jb.170.3.1116-1122.1988. J Bacteriol. 1988. PMID: 2830229 Free PMC article.
Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.
Tzipori S, Sheoran A, Akiyoshi D, Donohue-Rolfe A, Trachtman H. Tzipori S, et al. Clin Microbiol Rev. 2004 Oct;17(4):926-41, table of contents. doi: 10.1128/CMR.17.4.926-941.2004. Clin Microbiol Rev. 2004. PMID: 15489355 Free PMC article. Review.
Disruption of an internal membrane-spanning region in Shiga toxin 1 reduces cytotoxicity.
Suhan ML, Hovde CJ. Suhan ML, et al. Infect Immun. 1998 Nov;66(11):5252-9. doi: 10.1128/IAI.66.11.5252-5259.1998. Infect Immun. 1998. PMID: 9784530 Free PMC article.
A cluster of Escherichia coli O157:H7 infections with the hemolytic-uremic syndrome and death in California. A mandate for improved surveillance.
Shefer AM, Koo D, Werner SB, Mintz ED, Baron R, Wells JG, Barrett TJ, Ginsberg M, Bryant R, Abbott S, Griffin PM. Shefer AM, et al. West J Med. 1996 Jul-Aug;165(1-2):15-9. West J Med. 1996. PMID: 8855679 Free PMC article.

References

1. Infect Immun. 1985 Jan;47(1):242-6 - PubMed
1. Infect Immun. 1984 Mar;43(3):1027-32 - PubMed
1. Infect Immun. 1982 Oct;38(1):267-72 - PubMed
1. Infect Immun. 1983 Jul;41(1):430-3 - PubMed
1. Nature. 1970 Aug 15;227(5259):680-5 - PubMed

Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli - PubMed